Kornimate/medical-research-clean huggingface dataset:
the use of home spirometry in the monitoring of patients with acute exacerbation of asthma

Conditions: Asthma Attack

Summary: after outpatient clinic visit, asthmatic patients with worsening of symptoms (including dyspnea, wheezing, chest tightness, cough, activity limitation, awaken in the midnight due to discomfort) and are diagnosed of acute exacerbation by physician, will be recruited. the patients are asked to record symptoms using asthma symptom diary (asd) with home spirometry simultaneously for 14 days. visit 1 (day 1) all patients will be evaluated the following: 1. record the patients' demographics (age, gender, race), baseline characteristics, comorbidities, health care resources use (visits, lab tests, hospitalization and cost), pharmacological and non-pharmacological treatments 2. blood sampling for eosinophils, eosinophil cationic protein (ecp) and immunoglobulin e (ige) as clinically indicated (if no data available within one year for the last two) 3. the study assistant will introduce to the patient how to manipulate the home spirometry and its app, and to record the daily asthma symptoms by using the asd on the mobile phone. visit 2 (day 15) all patients will be arranged outpatient clinic follow up 2 weeks later from the first visit. the outpatient clinic physician will check the home spirometry report and asd symptom score in the past 2 weeks, and have a well explanation of these results. statistical analysis the usage of digital function including input asd, and the lung function from portable spirometer in study arm will be demonstrated by descriptive statistics.


Eligibility criteria:
inclusion criteria: * age 20 to 75 years old asthmatic patients under regular treatment for at least 3 months. * patients in asthma acute exacerbation (symptoms onset within 1 week) and received oral corticosteroid for more than 3 days. exclusion criteria: * refuse to provide inform consent. * patients with chronic obstructive pulmonary disease. * patients who receive more than 20mg prednisone or equivalent dose per day. * patients who are incapable of using smart phone.
characterization of the neo-squamous epithelial barrier

Conditions: Barrett's Esophagus With Dysplasia

Summary: to prospectively assess the functional aspects of the the esophageal squamous epithelial barrier and correlate this with tissue inflammation and intercellular space dilation in patients who have successfully completed endoscopic radiofrequency ablation versus balloon cryotherapy for barrett's esophagus related metaplasia.

the investigators will measure and correlate mucosal impedance (measured using a novel endoscopic mucosal impedance catheter), intercellular space as measured with transmission electron microscopy and tissue levels of prostaglandin e2 in patients undergoing surveillance following successful endoscopic therapy (defined as two negative endoscopic surveillance histology for intestinal metaplasia). mucosal impedance will be measured by an endoscopic probe. research biopsies will also be obtained for measurement of tissue levels of prostaglandin e2 and intracellular space with transmission electron microscopy. volumetric laser endomicroscopy will measure the precise thickness of and area of subsquamous structures underneath the neosquamous epithelium.

Eligibility criteria:
inclusion criteria: * adults (age 18-90) who underwent an ablative program for be exclusion criteria: * patients that have not achieved complete remission of intestinal metaplasia. * patients unable to consent. * pregnant women
impact of combined of lantus(insulin glargine) and lyxumia (lixisenatide) on insulin secretion and gastric emptying

Conditions: Diabetes Mellitus

Summary: impact of combined lantus (insulin glargine) and lyxumia(lixisenatide) on insulin secretion and gastric emptying

impact of combined lantus (insulin glargine) and lyxumia(lixisenatide) on insulin secretion and gastric emptying

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus diagnosed at least one year before the screening visit not previously treated with glitazones, insulin or glp-1 agonists * inadequately controlled diabetes mellitus exclusion criteria: * subjects with type 1 diabetes, maturity onset diabetes of the young (mody) or secondary forms of diabetes such as due to pancreatitis
a study of trv130 for the treatment of pain after abdominoplasty

Conditions: Pain

Summary: the primary objective is to evaluate the analgesic efficacy of iv trv130 compared with placebo in patients with acute postoperative pain following abdominoplasty.

the primary objective is to evaluate the analgesic efficacy of intravenous (iv) trv130 administered via patient controlled analgesia device (pca) compared with placebo administered via pca in patients with moderate to severe, acute postoperative pain following abdominoplasty.

Eligibility criteria:
inclusion criteria: * \>=18 and \<=65 years of age. * plans to undergo an abdominoplasty procedure with no additional collateral procedures. * is able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure. exclusion criteria: * asa physical status classification system classification of p3 or worse. * has surgical or post-surgical complications. * has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs. * has previously participated in another trv130 clinical study.

Keywords: pain abdominoplasty pca
safety and efficacy of bictegravir + emtricitabine/tenofovir alafenamide versus dolutegravir + emtricitabine/tenofovir alafenamide in hiv-1 infected, antiretroviral treatment-naive adults

Conditions: HIV-1 Infection

Summary: this study will evaluate the efficacy, safety and tolerability of bictegravir (bic) + emtricitabine/tenofovir alafenamide (f/taf) fixed dose combination (fdc) versus dolutegravir (dtg) + f/taf in hiv-1 infected, antiretroviral treatment-naive adults. this study will also evaluate the pharmacokinetic (pk) profile of bic, emtricitabine and taf.


Eligibility criteria:
key inclusion criteria: * antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent) * plasma hiv-1 rna levels ≥ 1,000 copies/ml at screening * screening genotype report provided by gilead sciences must show sensitivity to tenofovir (tfv) and emtricitabine (ftc) * adequate renal function as measured by estimated glomerular filtration rate ≥ 70 ml/min according to the cockcroft-gault formula * cd4+ cell count ≥ 200 cells/µl at screening key exclusion criteria: * a new aids-defining condition diagnosed within the 30 days prior to screening as defined in the study protocol * prior use of antiretrovirals in the setting of pre-exposure prophylaxis (prep) or post exposure prophylaxis (pep) * chronic hepatitis b virus (hbv) infection * hepatitis c infection (individuals who are hepatitis c virus (hcv) ab positive, but have a documented negative hcv rna, are eligible) * active, serious infections (other than hiv-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline * participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: adult hiv naive
juvenile primary fibromyalgia syndrome (jpfs) in an adolescent psychiatric population

Conditions: Juvenile Primary Fibromyalgia Syndrome

Summary: the purpose of this study was to identify clinical characteristics and estimate the prevalence of juvenile primary fibromyalgia in a female inpatient psychiatric population. the secondary purpose of this study was to determine the efficacy of an intervention (psychoeducational seminar and relaxation technique) on reducing the symptoms of juvenile primary fibromyalgia syndrome. we looked at the short-term and long-term effects of this intervention in comparison to the control (skin care seminar).

the specific aims of phase one of this study were to estimate the prevalence of juvenile primary fibromyalgia syndrome (jpfs) in an inpatient female psychiatric population and to identify characteristics associated with jpfs in this population. we chose to explore two primary hypotheses. because of the common link between adult fibromyalgia and anxiety and depression, we hypothesize that those with jpfs will score higher on measures of these symptoms. given the adult literature on the suspected link between physical and or sexual abuse and adult fibromyalgia, we also hypothesized that adolescents who meet criteria for jpfs will have higher rates of sexual and physical abuse. the other specific aim of this study was to determine the short- and long-term impact of an intervention on reduction of jpfs symptoms. the intervention was a psychoeducational seminar on jpfs (pain management, diet, exercise and sleep hygiene) followed by a relaxation technique (audio-guided cd). the control group was involved in an educational seminar on skin care (without relaxation technique). study measures were obtained immediately before and after the intervention/control seminars (short-term) and 8 weeks after discharge (long-term). each group was discharged with a cd player and cd with relaxation technique or skin care seminar. participants recorded the use of the cd's and completed follow up questionnaires 8 weeks after discharge from the hospital.

Eligibility criteria:
inclusion criteria: * admitted to inpatient child psychiatric facility * between 12-18 years of age * in parental or family (relative as guardian) custody exclusion criteria: * in state custody * low intellectual functioning (i.e. iq less than or equal to 70) * active psychosis

Keywords: juvenile primary fibromyalgia adolescents psychiatry
posterior cornea in primary open angle glaucoma

Conditions: Glaucoma

Summary: characterization of posterior corneal changes in primary open angle glaucoma patients, using scheimpflug examination.

a cohort of primary open angle glaucoma (poag) patients is submitted to scheimpflug pentacam examination. the results are compared with a control group of age and central corneal thickness matched healthy subjects

Eligibility criteria:
inclusion criteria: * primary open angle glaucoma, with the diagnosis supported on structural and functional complementary exams according to the current european glaucoma society guidelines * healthy subjects from the general ophthalmology outpatient clinic exclusion criteria: * age inferior to 18 years old * primary closed angle glaucoma * secondary open angle glaucoma * previous intra-ocular surgery * known or suspected corneal disease * previous intra-ocular inflammation * previous ocular trauma

Keywords: glaucoma primary open angle glaucoma cornea
efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes

Conditions: T2DM

Summary: the randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes


Eligibility criteria:
inclusion criteria: * t2dm * 30≤ age≤70 years old * bmi 18.0-28.0 kg/m2 * hba1c ≥8.5% * negtive gad、ica、iaa * patients do not use antihyperglycemia drugs * patients use antihyperglycemia drugs for ≥8 weeks(exclusion of dpp-4 inhibitors and glp-1 receptor agonist) exclusion criteria: * t1dm,gdm * congestive heart failure (new york heart association functional classification iii-iv) * alt or ast\> 2 times above normal,gfr \<50ml/min * severe infection in the previous 3 months * severely acute or chronic diabetic complications * patients who were taking medications,known to affect glycaemic control, such as glucocorticoids(aside from antidiabetic medications) * history of pancreatitis * trauma or patients operating at a scheduled time * any mental health condition
a study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis

Conditions: Lupus Nephritis; Glomerulonephritis, Membranous

Summary: this is a prospective randomized open-label pilot study to compare mycophenolate mofetil in combination with corticosteroid treatment and tacrolimus in combination with corticosteroid treatment in membranous lupus nephritis. the change in urine protein excretion will be the primary outcome studied. the study duration will be 24 months for each patient.


Eligibility criteria:
inclusion criteria: * abnormal urine protein excretion and biopsy-proven membranous lupus nephritis

Keywords: membranous lupus nephritis
radiofrequency non-ablative in the treatment of genitourinary syndrome of menopause

Conditions: Genitourinary Syndrome of Menopause

Summary: the study is conducted in women at the menopause with a clinical diagnosis of genitourinary syndrome, which presents symptoms in of vulvovaginal atrophy and tract urinary and were treated with radiofrequency non ablative technique for capacitive transfer in intra-vaginal. all participants were evaluated by a physical therapist and did the exam of ph vaginal, cell maturation index and questionnaires. the participants made five sessions of radio frequency (rf) with an interval of seven days between them. the application of rf was performed by physical therapist trained in the technique of radio frequency through the capenergie brand device with capacitive transfer method using non-ablative handle with active electrode intra-vaginal and coupling electrode placed on the participant's back. for application, the participants were in gynecological position. the session had an average duration above 20 minutes. the temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes in the anterior wall and 2 minutes more in the posterior wall of vagina.


Eligibility criteria:
inclusion criteria: * will be women in menopause until 65 years of age with clinical complaints of genitourinary syndrome of menopause and who agree to voluntarily participate in the research. exclusion criteria: * will be excluded from the study participants with limited understanding, with neurological degenerative chronic diseases, sensory deficit in the genital region, users of pacemaker and intrauterine device of cooper and women under hormone therapy under six months
efficacy and safety of different dose of tirofiban in interventional treatment of complex coronary artery disease

Conditions: Coronary Artery Disease

Summary: the aim of the study is to investigate the efficacy and safety different dose of gpiib/iiia inhibitor (tirofiban) in interventional treatment of complex coronary artery disease ,which include bifurcation lesion, left main lesion, multiple vessel disease, intracoronary thrombus, syntax score\>26,chronic total occlusion disease. the primary endpoint is all-cause mortality. secondary endpoints are incidence of major bleeding and the rate of site access complication.


Eligibility criteria:
inclusion criteria: * patients were recruited from those undergoing pci with a planned placement of an intracoronary stent * including patients with unstable angina pectoris, acute coronary syndrome or nstemi * experienced ischaemic pain at rest * lasting 10 minutes and occurring within 7 days before enrollment * as well as one of the following: ecg changes: new or presumably new st-segment depression greater than or equal to 0.1 mv (1 mm), or transient (\< 30 minutes) st-segment elevation greater than or equal to 0.1 mv (1 mm) in at least 2 contiguous leads -abnormal cardiac enzymes within the 24 hours before enrollment, defined as elevated troponin i defined as elevated troponin i (above the normal reference - * high-risk angiographic features :lesion/anatomy related bifurcation lesion, left main lesion, multiple vessel disease, intracoronary thrombus, syntax score \> 26 and chronic total occlusion disease. exclusion criteria: * increased bleeding risk: ischaemic stroke within the last year or any previous haemorrhagic stroke, tumour or intracranial aneurysm; * recent (\<1 month) trauma or major surgery (including bypass surgery); * active bleeding * unexplained clinically significant bleeding, thrombocytopenia (platelet count \< 100 x 109/l) or history of thrombocytopenia with gp iib/iiia, heparin or enoxaparin therapy * angina from secondary causes such as severe uncontrolled hypertension (systolic blood pressure \> 180 mm hg despite treatment) * valvular disease, congenital heart disease, hypertrophic cardiomyopathy, - thrombolytic therapy within preceding 24 hours * receiving antiiib/iiia therapy * creatinine clearance of \<30 ml/min
which balance test is more effective when evaluating stroke patients with a tele-assessment?

Conditions: Stroke

Summary: the aim of this study is to compare the feasibility levels and advantages of balance tests applied with tele-assessment methods to clinical application methods in stroke patients and to reveal their effectiveness.

the aim of this study is to compare the feasibility levels and advantages of balance tests applied with tele-assessment methods to clinical application methods in stroke patients and to reveal their effectiveness. stroke patients who are referred to i̇stinye university bahçeşehir liv hospital physiotherapy and rehabilitation unit at march-september for physiotherapy and meet the inclusion criteria will be included in the study. the patient assessment form which were prepared by the researcher and the standardized mini mental test, the rankin scale, timed get up and go test, berg balance scale, tinetti balance and gait test in order to evaluate the balance and walking of the participants due to stroke and to compare the applicability level of the tests applied with the tele- assessment method and tests will be completed by individuals who agreed to participate in the study and / or the researchers who carried out the study.

Eligibility criteria:
inclusion criteria: * sufficient cognitive function for communication (standardized mini-mental test score\> 24) * not dependent on bed or wheelchair. (1 ≤ modified rankin scale score \<5) * balance problem (timed get up and go test score\> 12 sec) * providing the necessary technological competence for remote video communication at home * near a relative who can accompany you during the assessment * age 20-80 years * speaking turkish exclusion criteria: * individuals with a neurological and orthopedic disease other than stroke, whose vision and auditory function are affected by stroke, and those with aphasia will not be included in the study.

Keywords: tele-assessment balance stroke
descriptive study of cardiac output during rehydration with recombinant human hyaluronidase in pediatrics

Conditions: Dehydration; Cardiac Output; Pediatrics

Summary: the purpose of this study is to non-invasively study the reflective changes in cardiac output as response to fluid therapy in the pediatric moderate hypovolemia/dehydrated pediatric patients using sub-q rehydration using hylenex augmented subcutaneous infusion of fluids and electrolytes compared to intravenous methods.

this is an open-labeled, single-center phase iv clinical trial. the study will consist of patients with moderate hypovolemia/dehydration requiring parenteral rehydration. it is expected that this study will describe the onset or change in cardiac output using hylenex augmented subcutaneous rehydration from ages 2 months up to 3 years and at a flow rate satisfying clinical needs, especially in reference to changes in cardiac output observed in standard intravenous rehydration.

Eligibility criteria:
inclusion criteria: * patients presenting to the emergency department (ed) with moderate dehydration (gorelick dehydration classification : presence of 3-6 moderate signs and symptoms) requiring parenteral rehydration. * patient has not successfully received oral or iv fluids immediately prior to enrollment * patient's legally authorized representative has signed the informed consent and is willing for the patient to receive hylenex augmented sub-q rehydration exclusion criteria: * patient in shock or a life-threatening situation * immunocompromised, history of abscess or cellulitis, abscess \&/or cellulitis caused by methicillin-resistant staphylococcus aureus (mrsa), family history of abscess or cellulitis * requires iv therapy for another indication * has an indwelling catheter * has already received rehydration therapy by iv route within the last 48 hours or substantial oral fluid in the immediate time period of enrollment * has a condition precluding sub-q injection or infusion site evaluation in the upper middle back area or at another elected site of infusion * has a reason for hospital admission or extended ed stay other than dehydration * has an known hypersensitivity to hyaluronidase or another ingredient in the formulation of hylenex * has a know hyponatremia \ 155 meq/l * has a know hypokalemia \<3.0 meq/l * has a medical condition likely to interfere with the patients ability to fully complete the study protocol or the ability to have the protocol-specified assessments * has a medical history, screening physical exam finding or historical clinical lab result that in the opinion of the investigator would preclude the patients safe participation in the is study or which might adversely effect the interpretation of the study results * patient participated in a study of any investigational drug or device within 230 days prior to enrollment in this study

Keywords: cardiac output dehydration pediatrics
[s,s]-reboxetine long term safety study in post-shingles pain.

Conditions: Pain

Summary: the purpose of this study is to assess the long term (up to 2 years) safety and tolerability of \[s,s\]-reboxetine in patients with pain after shingles.


Eligibility criteria:
inclusion criteria: * patients must have pain present for more than 3 months after healing of the shingles skin rash. * patients at screening must have a score of \>/=40mm on the pain visual analogue scale. exclusion criteria: * patients with significant hepatic impairment. * patients with other severe pain, that may impair the self-assessment of pain due to postherpetic neuralgia (pain after shingles).